ClinicalTrials.gg
RecruitingNCT07362082Updated Sep 21, 2026

A Clinical Trial of Telehealth Treatment for Opioid Use Disorders

An interventional study of RecoveryPad platform in Opioid Use Disorder, sponsored by Yale University. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-21.

Sponsored by Yale University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Sep 2026; still recruiting 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
470
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 106 studies in Opioid-Related Disorders by Yale University — 20 open to participants now, 24 under way, 1 of them phase 3. Opioid-Related Disorders · Yale University.

Planned enrollment
14th of 94
470 · median 62
Started
2026
with 7 others
No phase
44 of 106
7 open now
Primary completion
2027-10
later than 11 of 23 live
Registered
100th of 106
by date

Among the 106 studies in Opioid-Related Disorders by Yale University, this one is the 14th largest by planned enrollment of the 94 interventional ones that give a count, is one of 8 that started in 2026, is one of 44 with no phase, reaches primary completion later than 11 of the 23 other live ones, and was the 100th registered.

Opioid-Related Disorders

1,476 studies on the registry are indexed under Opioid-Related Disorders; 293 are open to participants now.

Browse Opioid-Related Disorders studies →

Open to participants now

20 of the 106 studies in Opioid-Related Disorders by Yale University are open now, in 4 countries. Recruiting first, the newest first:

14 more — sign in →

By country, each count listing its studies:

All 20 open studies →

Who these studies take

Of the 213 Opioid-Related Disorders studies recruiting now, 123 (58%) set no upper age limit and 76 (36%) stop at 75 or younger; 14 take children under 18; 53 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 106 studies in Opioid-Related Disorders by Yale University, or all of them as a file.
02

Study summary

This trial will assess effects of enrollment in a comprehensive telehealth platform, RecoveryPad (RP), in adults with moderate or severe opioid use disorder.

03

Conditions studied

  • Opioid Use Disorder
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Can speak, read and write in English
  • Provision of signed and dated form
  • Screened positive for OUD, moderate or severe, based on the Diagnostic and Statistical Manual-5th Edition
  • Have a working cell phone number and working device that can access a web browser and receive texts (i.e., smartphone, tablet or computer)
  • Can provide a working email address OR be willing to create one

Exclusion criteria

Exclusion Criteria:

  • Current use of buprenorphine, methadone, or naltrexone for a substance use disorder
  • Pregnancy
  • Known current suicide risk based on participant self-report
  • On parole or incarcerated at time of enrollment based on participant self-report
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
470 participants (estimated)

Study arms

  • Experimental
    RecoveryPad platform

    Participants randomized to RecoveryPad platform

    Device: RecoveryPad platform

  • No intervention
    Treatment as usual

    Treatment as usual: referrals to harm reduction and other community resources that are already being given to individuals in the various community and healthcare settings from which these participants are being recruited.

Interventions

  • DeviceRecoveryPad platform

    Telehealth platform to enhance motivation and engagement in treatment for OUD

06

What researchers measure

Primary outcomes

  1. Attendance for MOUD

    Overall attendance will be measured by attendance (yes or no) at the first MOUD appointment within 30 days of enrollment.

    Time frame: Up to 30 days

Secondary outcomes

  1. Attendance for MOUD

    Overall attendance will be measured by attendance (yes or no) at the first MOUD appointment within 31 to 90 days of enrollment.

    Time frame: Up to 90 days

  2. Engagement with MOUD

    Engagement will be measured by demonstrated maintained attendance with MOUD treatment within 90 days of enrollment.

    Time frame: Up to 90 days

  3. Overdose Events at 30 Days

    A self-report of the number of subsequent overdose events within 30 days.

    Time frame: Up to 30 days

  4. Overdose Events at 90 Days

    A self-report of the number of subsequent overdose events within 90 days.

    Time frame: Up to 90 days

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — In accordance with the HEAL Public Access and Data Sharing policy, de-identified IPD underlying the results reported in study-related publications will be shared. These will include participant-level data such as demographics/baseline characteristics, randomization results, and primary and secondary outcome measures.Direct identifiers will not be shared. Data will be de-identified using accepted standards.

Time frame: The de-identified IPD and relevant supporting documentation will be available no later than 12 months after completion of primary analyses and publication of the primary results, or within the period required by the HEAL Initiative data sharing policy. Data will remain available for a minimum of 3 years after the initial release date, subject to repository support and other policy requirements.

Access criteria: All shared data and associated supporting documentation will be uploaded to the National Addiction and Health Data Archive Program.

Data sharing details ↗ · www.icpsr.umich.edu

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2026 (actual). Primary completion is estimated for Oct 2027, 12 months after the start.

Of 465 non-industry interventional studies with no phase under Opioid-Related Disorders, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 47. This study's planned 12 months is below that.

Counting every sponsor, half of 496 studies reached it within 29 months; a quarter within 13 and three quarters within 46.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 21, 2026
First posted
Jan 23, 2026
StartActual
Sep 11, 2026
Primary completionEst.
Oct 1, 2027
CompletionEst.
Dec 1, 2027
Last update
Sep 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07362082
Lead sponsor
Yale University
Collaborators
National Institute on Drug Abuse (NIDA), City University of New York, School of Public Health
Responsible party
Sponsor
First posted
Jan 23, 2026
Start date
Sep 11, 2026
Primary completion
Oct 1, 2027 (estimated)
Completion
Dec 1, 2027 (estimated)
Last update
Sep 21, 2026

Study contacts

Rebekah Heckmann, MD
Contact
rebekah.heckmann@yale.edu
(203) 737-8335
Rebekah Heckmann, MD
principal investigator · Yale University
Nasim Sabounchi, PhD
principal investigator · CUNY Graduate School of Public Health & Health Policy

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion